Alzheimer’s disease (DA) remains a major therapeutic challenge, and selective butyrylcholinesterase (BChE) inhibition has emerged as a promising strategy for symptomatic treatment, particularly in advanced stages. Herein, a series of novel quinoline–acylguanidine hybrids was designed through a bioisosteric replacement...
M. C. dos Santos, Átila M. Mofati, N. Nadur et al.· Scientia Pharmaceutica· 0 citations
Alzheimer's disease (AD) is a progressive and multifactorial neurodegenerative disorder involving metabolic dysfunction, neuroinflammation, mitochondrial impairment, synaptic failure, and neuronal loss. Although amyloid-beta deposition and neurofibrillary tangles composed of hyperphosphorylated tau remain central patho...
Jefferson Muniz Alves da Silva, A. Kümmerle, D. A. Rodrigues et al.· Future Medicinal Chemistry· 0 citations
It is demonstrated that while FA and Qc effectively modulate the redox imbalance caused by Aβ42, their antioxidant effect does not directly translate into cellular protection against β-amyloid cytotoxicity, and mitigating this condition alone is insufficient to neutralize the fundamental pathological mechanisms that co...
Rodrigo P. Osorio, D. C. N. Grillo, T. A. Cruz et al.· ARACÊ· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
